Journal of Chemistry

Journal of Chemistry / 2012 / Article

Open Access

Volume 9 |Article ID 782738 | 6 pages | https://doi.org/10.1155/2012/782738

Analytical Method Development and Validation of Exemestane Tablet by UV Spectrophotometry

Received02 Nov 2011
Accepted07 Jan 2012

Abstract

The present research work discusses the development and validation of a UV spectrophotometric method for Exemestane. Simple, accurate and cost efficient spectrophotometric method has been developed for the estimation of Exemestane in Tablet dosage form. The optimum conditions for the analysis of the drug were established. The maximum wavelength (λ max) was found to be 246 nm. The percentage recovery of Exemestane was in the 98.7±0.4. Beers law was obeyed in the concentration range of 2-14 µg/mL. Calibration curves shows a linear relationship between the absorbance and concentration. The line equation y=0.05954x+0.0000 with r2 of 0.9938 was obtained. Validation was performed according to ICH guidelines for Linearity, accuracy, precision, LOD and LOQ. The sample solution was stable up to 36 hours. The proposed method may be suitable for the analysis of Exemestane in tablet formulation for quality control purposes.

Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

626 Views | 5314 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.